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Abstract
Type 1 diabetes can reduce vision by affecting various parts of the eye. Proactive, in‐
terdisciplinary coordination of treatment and timely referrals can aid in the minimiza‐
tion of visually threatening complications, significantly enhancing patient quality of
life. The main causes of visual impairment in diabetes are proliferative diabetic retin‐
opathy and macular edema. Until recently, the mainstay of treatment for both condi‐
tions was retinal laser, which prevented significant vision loss but was much less
effective at improving vision, especially in macular edema. Over the past decade, ex‐
citing new advances in treating diabetic eye disease, namely intraocular steroid and
antivascular endothelial growth factor injections, have greatly improved the visual
prognosis for the majority of patients with diabetic eye disease.
Keywords: Diabetic retinopathy, Macular edema, Laser, Intraocular injection, Cata‐
ract
1. Introduction
Type 1 diabetes is a complex metabolic disease that involves multiple organ systems which
can cause severe visual impairment. Almost all ocular structures may be afflicted in diabetes
including: the extraocular muscles, the intraocular lens, the optic nerve, and the retina.
Diabetes is the leading cause of blindness between the ages of 20 and 74 in many developed
countries. Individuals with diabetes are 25 times more likely to become legally blind than
individuals without diabetes. The aspect of diabetic eye disease most responsible for vision
loss is diabetic retinopathy, which accounts for ¼ of blind registrations in the Western world
[1,2]. There are two main pathways by which diabetic retinopathy affects vision; fluid
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accumulation in the center of vision, or macular edema, and the formation of pathological
retinal vessels also known as proliferative diabetic retinopathy.
Prevention of severe visual impairment in type 1 diabetes includes: optimal glycemic control,
the treatment of ancillary risk factors such as hypertension, and regular screening for early
diagnosis and treatment of ocular complications.
In the following chapter, we will describe how diabetes affects different ocular structures and
discuss the treatment options available today to combat these complications.
2. Extraocular muscles
Patients with diabetes may present with a sudden onset of diplopia (double vision). This is
usually caused by a paresis of one of the extraocular muscles due to microvascular damage to
the third, fourth, or the sixth cranial nerves [3,4].
When the extraocular muscle deficit is due to microvascular complications of diabetes the
prognosis is good. Recovery of ocular motor function generally begins within three months of
onset and recovery is usually complete. Although the diplopia can be debilitating, due to the
generally limited course of these complaints, patients can usually be effectively managed
conservatively with eye patching. When diplopia is from large divergence of the visual axes,
patching one eye is the only practical short-term solution. When the deviation is smaller, the
diplopia often can be resolved by using glasses with a horizontal or vertical prism or both.
Surgery is rarely indicated.
If patients do not recover from a cranial nerve palsy within 6-12 months, eye muscle surgery
to treat persistent and stable angle diplopia should be considered. These patients should
consult with a neuro-ophthalmologist for continuing care.
3. Intraocular lens: Cataract
Cataract is a common cause of visual impairment in patients with diabetes. The Framingham
study [5] revealed a three- to four fold increased prevalence of cataract in diabetic patients
under the age of 65, and up to a twofold increased prevalence in patients above 65. Duration
of diabetes and quality of glycemic control are the major risk factors for early cataract devel‐
opment [5].
Recurrent high levels of glucose in the lens lead to the glycolation of lens proteins from
increased nonenzymatic glycation and oxidative stress to the lens [6]. This causes diabetic
patients to develop age-related lens changes similar to nondiabetic age-related cataracts,
except that they tend to occur at a younger age [7]. Several studies have analyzed the effect of
vitamin and antioxidant supplements, such as vitamin C, E, and beta carotene and zinc, on
preventing or slowing progression of age-related cataracts in diabetes without showing any
statistically significant benefit with their use [6].
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Early cataracts may cause mild visual impairment that can be managed reasonably with
spectacle correction. Cataract surgery is indicated when visual function is significantly
impaired by the cataract or if the cataract obscures the view of the retina and makes the
diagnosis and treatment of diabetic retinopathy difficult.
Cataract surgery is safe in diabetic patients and there is a 95% success rate in terms of improved
visual acuity [6]. Good glycemic control, fluid and electrolyte balance should be maintained
perioperatively and the patient’s treating physician and anesthesiologist should be involved
in the process. It is recommended that the surgery be scheduled in the morning to minimize
changes in the patient’s usual schedule [8].
Some controversy exists regarding a potential association between cataract surgery and a
subsequent worsening of diabetic retinopathy. Patients should be made aware of this risk
preoperatively. Cataract surgery and its effect on diabetic retinopathy will be discussed in
more detail in section 7.3.2.
4. Cornea
Corneal disorders secondary to diabetes (diabetic keratopathy) are increasingly recognized as
a cause of ocular morbidity associated with diabetes. Patients with diabetes have structural
changes of the corneal basement membrane that contributes to defects in the adhesion of
corneal epithelial cells to the deeper stromal tissue [9]. This increases the risk of recurrent
corneal erosions. In addition, accumulation of sorbitol in the cornea during periods of
hyperglycemia leads to hypoesthesia (a loss of corneal sensation). Both hypoesthesia and
epithelial adhesion dysfunction occur more frequently with increased severity and duration
of diabetes. In patients with more long-standing or advanced diabetes, any corneal epithelial
injury, either from trauma, during ocular surgery or from routine contact lens use, may result
in prolonged healing times. This increases the risk of severe complications such as bacterial
infiltration and ulceration.
Treatment of diabetic keratopathy is multifaceted, including artificial tears for mild cases, and
the use of topical antibiotics, a bandage contact lens, eye patching, or closure for more severe
cases.
5. Iris
Rubeosis iridis, neovascularization of the iris, is a serious complication of diabetes which
occurs in patients with severe diabetic retinopathy [3]. Severe retinal ischemia stimulates the
formation of numerous intertwining blood vessels on the anterior surface of the iris. These
vessels can block aqueous outflow from the anterior chamber, leading to a sharp and persistent
rise in intraocular pressure. This complication is known as neovascular glaucoma. This type
of glaucoma is hard to treat and is often associated with pain from very high ocular pressure.
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Topical medical therapy used commonly in other forms of glaucoma is less effective. Treatment
should include aggressive control of the underlying diabetic retinopathy. The treatment of
diabetic retinopathy will be discussed in more detail in section 7.
6. Retina – Diabetic retinopathy
Damage to the retinal capillaries, known as diabetic retinopathy, is the hallmark of diabetic
eye disease. This condition is the major cause of blindness and visual disability in patients with
type 1 diabetes.
There are two main pathways by which diabetic retinopathy can reduce vision: macular edema
and proliferative retinopathy. These conditions can appear concomitantly or separately with
the treatment protocol tailored to the relative severity each condition.
Macular edema develops when damaged retina vessels leak fluid and protein. These deposits
collect on or under the macula of the eye where central vision is processed. This causes the
macula to thicken and swell and may distort central vision.
Proliferative retinopathy occurs when diffuse injury to retinal vessels severely impairs retinal
oxygenation. The hypoxia induces the release of proteins which stimulate the growth (or
proliferation) of new, fragile retinal vessels. These new vessels have a propensity to bleed,
which severely reduces vision.
In the following sections, we will discuss how retinopathy and macular edema develop and
the various treatment options available to patients today, with a focus on exciting recent
developments.
6.1. Epidemiology
Diabetic retinopathy is one of the most frequent causes of preventable blindness in working
aged adults (20-74 years) [1,10]. In the USA, an estimated 86% of patients with type 1 diabetes
have some degree of diabetic retinopathy. Data from the Wisconsin Epidemiologic Study of
Diabetic Retinopathy (WESDR) showed that within 5 years of diagnosis of type 1 diabetes,
14% of patients developed retinopathy, with the incidence rising to 74% by 10 years [11,12]. In
people with retinopathy at the WESDR baseline examination, 64% had their retinopathy
worsen, 17% progressed to proliferative diabetic retinopathy (PDR), and about 20% developed
diabetic macular edema during 10 years of follow-up.
The WESDR data in type 1 diabetics showed that 25 years after diagnosis, 97% of patients
developed retinopathy, 43% progressed to PDR, 29% developed diabetic macular edema, and
3.6% of patients younger than 30 at diagnosis were legally blind [11]. The WESDR results also
showed a reduction in the yearly incidence and progression of diabetic retinopathy during the
past 15 years [12]. This may be signaling an improved ocular prognosis for diabetics today,
possibly due to recent advances in glycemic control, ophthalmic treatment, and patient
education.
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The course of diabetic retinal disease in children with type 1 diabetes is fairly benign. Severe
vision-reducing complications are uncommon in children before puberty [13].
6.2. Risk factors
There are several risk factors which influence the development and progression of diabetic
retinopathy. The following list contains most of the important risk factors known today.
Modifiable risk factors:
1. Hyperglycemia: Good glycemic control has been shown to significantly prevent the
development and progression of diabetic retinopathy. Every 1% decrease in hemoglobin
A1C leads to a 40% reduction in the risk of developing retinopathy, a 25% reduction in the
risk of progression to vision-threatening retinopathy, and a 15% reduction in the risk of
blindness [1,14,15].
2. Hypertension: Good blood pressure control is important in reducing the risk of retinop‐
athy. Every 10 mmHg reduction in systolic blood pressure leads to a reduction of 35% in
the risk of retinopathy progression and a reduction of 50% in the risk of visual loss [1].
3. Obesity: Obesity (BMI>30 kg/m(2)) is an important risk factor for diabetic retinopathy
progression in type 1 diabetes, independent of HbA1c levels [16].
4. Smoking: There is some evidence that smoking may be a risk factor in progression of
retinopathy in type 1 diabetes [17].
Nonmodifiable risk factors:
1. Diabetes duration: The longer the duration of diabetes, the higher the risk of developing
diabetic retinopathy and of having a severe manifestation of this disease [1].
2. Genetic factors: The Diabetes Control and Complications Trial [18] showed a heritable
tendency for developing diabetic retinopathy, regardless of other risk factors. The
abnormal development of new blood vessels is regulated by protein called vascular
endothelial growth factor A (VEGF –A). Variation in the sequence of this gene is associated
with the development of severe diabetic retinopathy [19].
3. Ethnicity: Diabetic retinopathy in America is more prevalent among African Americans,
Hispanic and south Asian groups than in Caucasians with otherwise similar risk profiles
[1].
4. Gender: there is an observed gender dimorphism with younger females being at greater
risk for diabetic retinopathy early in the course of diabetes [20] and males demonstrating
greater risk later in life [21].
Other risk factors:
Pregnancy: Pregnancy is associated with worsening of diabetic retinopathy [22]. All pregnant
women need to be closely monitored throughout pregnancy. Pregnancy in type 1 diabetes is
discussed in further detail in section 7.3.1.




Diabetic retinopathy develops when hyperglycemia and other causal risk factors trigger a
cascade of biochemical changes which damage retinal blood vessels. Hyperglycemia increases
sorbitol levels via the action of aldose reductase increasing oxidative stress by reducing
intracellular levels of reduced glutathione, an important antioxidant [23]. Intracellular
hyperglycemia also increases synthesis of diacylglycerol, an activating cofactor for protein
kinase C (PKC). Activated PKC decreases the production of anti-artherosclerotic factors and
increases production of pro-artherogenic factors, pro-adhesive and pro-inflammatory factors
[23]. As well, intracellular hyperglycemia leads to a rise in intracellular N-acetylglucosamine
levels. This by-product reacts with serine and threonine residues in transcription factors,
resulting in pathologic changes in gene expression [23]. The final by-product of these patho‐
logical processes is increased inflammation and increased oxidative stress, which causes
endothelial cell dysfunction in retinal blood vessels.
Endothelial cell dysfunction induces retinal arteriolar dilatation, which increases capillary bed
pressure. This results in microaneurysm formation, vessel leakage, and rupture [1]. Vascular
permeability is also increased from loss of pericytes and increased endothelial proliferation in
retinal capillaries. The breakdown of the blood–retinal barrier allows fluid to accumulate in
the deep retinal layers where it damages photoreceptors and other neural tissues. This is the
mechanism by which macular edema reduces visual acuity.
In some capillaries there is endothelial cell apoptosis. Vessels become acellular, leading to
vascular occlusion and nonperfusion of local retinal tissue [23]. The resultant retinal ischemia
promotes the release of inflammatory growth factors, such as vascular endothelial growth
factor, growth-hormone-insulin growth factor, and erythropoietin [1]. These factors influence
neovascularization, the growth of new capillaries, which are generally ineffective in improving
tissue oxygenation as they often grow up toward the vitreous cavity.
6.4. Clinical features and classification
Diabetic retinopathy is classified as nonproliferative diabetic retinopathy (NPDR) when the
vascular changes are limited to the retinal surface. It is classified as proliferative diabetic
retinopathy (PDR) in the more advanced stage when new blood vessels form, which grow
from the retinal surface up toward the vitreous cavity.
Diabetic macular edema occurs when leaky capillary beds allow fluid to accumulate in the
part of the retina responsible for central vision. This complication can occur in patients with
any level of underlying retinopathy from mild NPDR to severe PDR. Visual impairment is
usually related to the state of macular disease and the consequences of neovascularization such
as vitreous hemorrhage and retinal detachment. As such, the level of retinopathy does not
always correlate with visual function, and severe diabetic retinopathy can be present initially
without significant visual loss.
6.5. Diabetic macular edema
Diabetic macular edema (DME) is the complication of retinopathy responsible for most of the
moderate visual loss in retinopathy patients. The loss of vision is often very mild at first, but
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without effective treatment it can progress and patients can lose the ability to perform activities
of daily living such as reading and driving. Diabetic macular edema is assessed separately
from the stage of retinopathy (NPDR/PDR) and it can manifest along a different and inde‐
pendent course.
The edema evolves when damage to the macular capillary bed causes increased retinal
vascular permeability and fluid accumulation in the macula. Clinical examination can reveal
rings of hard exudates (lipid-filled macrophages) that delineate the area of focal leakage.
Optical Coherence Tomography (OCT) is a useful ancillary imaging technique in DME. Recent
technological advances in OCT technology have provided physicians with high-resolution
images of the retina in cross-sectional slices. Aside from demonstrating areas of retinal
thickening and intraretinal fluid, OCT obtains quantitative measurements of central retinal
thickness. Serial OCT examinations are often used as a noninvasive and accurate method
analyzing treatment response in DME patients [1].
Figure 1. Normal OCT of the macular region.
Figure 2. Macular edema: The OCT demonstrates the disruption of the normal macular anatomy due to macular edema.
Figure 3. Posttreatment OCT: The same patient as in Figure 2 after treatment with intravitreal injections. The edema
has been reabsorbed.
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6.5.1. Nonproliferative Diabetic Retinopathy (NPDR)
In NPDR, the retinal microvascular changes do not extend beyond the surface of the retina.
Clinical findings include microaneurysms (saccular enlargements of weakened capillaries),
intraretinal hemorrhages, hard exudates (lipid-filled macrophages), cotton wool spots (nerve
fiber layer infarcts), venous dilatations, and intraretinal microvascular abnormalities (dilated
preexisting capillaries) [1,10].
NPDR is classified as mild, moderate, or severe, reflecting the risk of progression to PDR (Table
1) as determined by the Early Treatment in Diabetic Retinopathy Study [24].
Figure 4. Nonproliferative diabetic retinopathy: Scattered hemorrhages (“dot and blot” shaped) can be seen through‐
out the retina.
6.5.2. Proliferative Diabetic Retinopathy (PDR)
Diabetic retinopathy advances to the proliferative stage when new vessels (neovasculariza‐
tions) are formed which grow up from the retinal surface toward the vitreous cavity. The
growth of these vessels is potentiated by the progression of diabetic retinal microvascular
disease, causing severe retinal ischemia. This induces the release of proangiogenic factors
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which promote the growth of these pathological vessels. Neovascularizations can be identified
clinically as a jumble of disorganized, fine vessels emanating from the organized retinal vessel
architecture. Angiography is also very effective at identifying neovascular lesions as the new
vessels are porous and leak fluorescent dye into the vitreous cavity.
The new vessels in PDR evolve in three stages. Initially, the fine new vessels grow with minimal
fibrous tissue. Then the new vessels increase in gauge and length with an increased fibrous
component. Finally, the vessels regress and the residual fibrovascular tissue along the posterior
surface of the vitreous body contracts.
Retinal neovascularizations (NV) are divided into two subtypes based on their relative risk of
causing severe visual loss as demonstrated by the Diabetic Retinopathy Study (DRS). Vascular
proliferations on or near the optic disc are termed NV-disc (NVD) and proliferations elsewhere
are termed NV-elsewhere (NVE). The presence of NVD carries the higher risk of severe visual
loss and requires more urgent treatment [25,26].
Figure 5. Neovascularization on the optic disc (NVD): The growth of fine new blood vessels can be seen on the optic
disc. Urgent treatment is indicated to reduce the risk of vitreous hemorrhage.
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PDR is graded from early to high risk according to the extent of the neovascular proliferations.
The DRS [25,26] defined high-risk PDR as the presence of either: NVD with a vitreous
hemorrhage, NVD larger than a quarter disc area without vitreous hemorrhage, or NVE larger
than half disc area with vitreous hemorrhage. Without treatment, patients with early PDR have
50% risk of developing high-risk PDR in 1 year and those with high-risk PDR have a 25% risk
of severe visual loss within 2 years. Treatment of PDR involving extensive peripheral laser
ablation of the retina is discussed section 7.2.3.
The most common complication of PDR is vitreous hemorrhage caused by bleeding from the
pathological neovascular vessels. Retinal detachments can also occur from the contraction of
the neovascular tissue connecting the retinal surface to the vitreous.
Visual acuity in the absence of macular disease is often very good in PDR until a complication
occurs; most commonly vitreous hemorrhage. This sudden transition from good vision to near
blindness is often traumatic for patients who were unaware of the severity of their diabetic eye
disease.
Figure 6. Vitreous hemorrhage with a neovascularization of the optic disc (NVD): The fragile blood vessels of the NVD
have ruptured and a vitreous hemorrhage has collected, partially obscuring the macula and severely limiting vision.
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Clinical Features Progression Risk
Mild NPDR Few microaneurysms 5% progress to PDR within 1 year
Moderate NPDR Microaneurysms and other
microvascular lesions
12-16% progress to PDR within 1 year
Severe NPDR (Meets 1 of 3 criteria) • Extensive intraretinal hemorrhages
and microaneurysms in all four
quadrants
• Venous beading in two or more
quadrants
• One IRMA
52% progress to PDR within 1 year
15% progress to high risk PDR within
1 year
Very severe NPDR Any two of the features
of severe NPDR
75% progress to PDR within 1 year
45% progress to high risk PDR within
1 year
Early PDR 50% risk of developing high risk PDR
in 1 year
High risk PDR 25% risk of severe visual loss within 2
years
Table 1. Clinical classification of nonproliferative and proliferative diabetic retinopathy
Figure 7. Traction Retinal Detachment: The neovascular tissue emanating from the optic disc and elsewhere has re‐
gressed leaving behind white fibrous tissue. This tissue has contracted and is distorting the retina in the macular re‐
gion.
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7. Treatment of diabetic retinopathy
The main goal of treatment of diabetic retinopathy is to prevent complications that can lead to
vision loss. Treatment should include both ocular therapy and systemic medical intervention.
7.1. Medical treatment
Hyperglycemia, hypertension, and hyperlipidemia are known risk factors for the development
and progression of diabetic retinopathy. Treating and controlling these factors is crucial to
preventing and limiting disease progression.
The Diabetes Control and Complications Trial [14] showed that intensive glycemic control
reduced both the risk of developing retinopathy and the rate of progression of existing
retinopathy. Intensive glycemic control reduced the risk for progression to severe NPDR and
PDR, and the incidence of diabetic macular edema. Every percent reduction in hemoglobin
A1C lowers the risk of retinopathy development by 30-40%.
Antihypertensive treatment with ACE (angiotensin-converting enzyme) inhibitors can slow
progression of diabetic nephropathy. The EUCLID study [27] investigated the effect of
Lisinopril on progression of retinopathy in normotensive type 1 diabetics. They found that
Lisinopril can decrease retinopathy progression in nonhypertensive patients who have type 1
diabetes with little or no nephropathy, although the mechanism is unclear. Unfortunately,
other studies investigating the effect of ACE inhibitors on the progression of DR in type 1
diabetics have shown no significant benefits.
7.2. Ocular therapy
Ocular therapy in diabetic retinopathy includes panretinal or focal laser photocoagulation,
intravitreal injections of either steroids or inhibitors of Vascular Endothelial Growth Factor
(VEGF), surgery, or a combination of the aforementioned treatments. The suitable treatment
regimen must be tailored individually for each patient and is based on clinical status of the
patient (ocular and systemic), previous treatments, and data from the several reported and
ongoing studies.
7.2.1. Diabetic macular edema treatment
Treatment options for diabetic macular edema (DME) include focal laser photocoagulation,
intravitreal injections of either steroids or anti-VEGF compounds, and surgery.
7.2.1.1. Focal laser treatment
Until recently, the mainstay of DME treatment was macular laser photocoagulation. Treatment
criteria are based on the ETDRS recommendations [24], which showed that eyes with macular
edema involving or adjacent to the central macula, defined as clinically significant macular
edema (CSME), benefited from macular laser treatment. Laser treatment reduced the risk of
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moderate visual loss (loss of three lines of vision) by 50% over 2 years compared with no
treatment [24].
Macular laser treatment for CSME involves the application of discrete laser burns to areas of
leakage in the macula. The treatment is not painful and can be repeated up to every 4 months.
Side effects of macular laser photocoagulation include: visual field loss, choroidal neovascu‐
larization, subretinal fibrosis, and inadvertent foveolar burns [10].
Modified photocoagulation techniques have been developed in response to these potential
complications. The target of macular laser treatment for CSME is retinal pigment epithelium
(RPE). Ideally, the laser energy would be absorbed only by the RPE and not spread to the
surrounding tissues. Unfortunately, in conventional argon laser photocoagulation visible
burns are created, indicating damage to the inner neural retina from the spread of thermal
energy beyond the RPE.
Subthreshold diode laser micropulse (SDM) therapy delivers short pulses, which cause less
thermal damage. Shorter laser exposure times confine the laser energy to a smaller zone,
inflicting less damage on the neural retinal and choriocapillaries. SDM laser has been shown
to be as effective as a conventional laser with fewer side effects [28].
7.2.1.2. Steroid injections
Inflammatory factors play an important role in the development of diabetic retinopathy.
Upregulation of adhesion molecules in blood vessels leads to leukostasis and the accumulation
of macrophages in the retinal vessels. These macrophages release angiogenic growth factors
[29] and cytokines which increase vascular permeability. Glucocorticoids block the action of
these macrophages and downregulate ICAM-1, which mediates leukocyte adhesion and
transmigration [30].
In addition, glucocorticoids alter the composition of endothelial basal membrane by changing
the local ratio of two laminin isoforms [31], suppressing basement membrane dissolution, and
strengthening tight junctions to limit permeability and leakage that cause macular edema [32].
For this reason, it has long been thought that ocular steroid injections may be beneficial in DME
treatment.
Intravitreal triamcinolone acetonide
Triamcinolone acetonide (TA) is a synthetic steroid of the glucocorticoid family with a
molecular weight of 434.50. In 2001–2002, the first reports were published of the use of
intravitreal injection of triamcinolone acetonide for DME [33,34]. The most common dose used
is 4 mg.
Sutter et al. [35] reported in a prospective, double-masked, and randomized trial comparing
4 mg intravitreal TA with sham injection (saline). This study reported that 55% of 33 eyes
treated with 4 mg of intravitreal TA improved by 5 or more letters of vision at 3 months
compared with 16% of 32 eyes treated with sham injection.
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The DRCR.net (diabetic retinopathy clinical research network) protocol I [36] studied the use
of 4 mg TA combined with macular laser. It found that TA combined with laser significantly
improved vision over macular laser alone in patients who had previously undergone cataract
surgery. In patients who had not previously undergone cataract surgery TA was much less
effective.
Potential side effects of corticosteroid injections include cataract formation and glaucoma.
Moreover, as the treatment effect wanes, patients require repeated injections that increase the
glaucoma and especially the cataract risk.
Instead of intermittent bolus therapy, it is thought that sustained release of a lower-dose
glucocorticoid may lead to greater efficacy with fewer complications. This has led to the
development of slow-release steroid implants.
Dexamethasone intravitreal implant
Dexamethasone is a strong synthetic member of the glucocorticoid class of steroid, with an
anti-inflammatory and immunosuppressant activity 30 times greater than cortisol and 6 times
greater than triamcinolone.
A sustained-release intravitreal dexamethasone (DEX) implant (Ozurdex®, Allergan Inc,
Irvine, CA) is biodegradable and is placed in the vitreous cavity using a 22-gauge applicator
through a small self-sealing puncture.
Dexmathasone implants have been examined in several large studies; The PLACID study [37]
compared a DEX implant (0.7 mg) to treatment with focal laser. This 1-year study did not show
a statistically significant visual improvement with the DEX implant.
The MEAD study [38] combined the results of two multicenter 3-year sham-controlled,
masked, randomized clinical studies comparing DEX injection to focal laser treatment. Patients
receiving the 0.7 DEX implant required mean of 4.1 injections over 3 years. The average visual
improvement with the 0.7 mg DEX implant was +6 letters versus +1 letter with focal laser. Rates
of cataract-related adverse events in phakic eyes were 67.9% and 20.4% in the DEX implant 0.7
mg, and sham groups, respectively. Two patients (0.6%) in the DEX implant 0.7 mg group
required trabeculectomy for severe glaucoma. Based on the MEAD study, the Food and Drug
Administration (FDA) approved DEX implants for use in DME.
Fluocinolone acetonide
Fluocinolone acetonide is a corticosteroid with average mass of 452 Da. ILUVIEN is a non‐
bioerodable intravitreal implant in a drug delivery system containing fluocinolone acetonide.
The fluocinolone acetonide (FA) intravitreal implant [39] is administered in the clinic using a
25-gauge inserter designed to release the drug slowly over 36 months. Unlike the DEX implant,
it is not bioerodable.
The FAME studies [40] were two phase 3 clinical trials examining the effect of long-acting
fluocinolone acetonide inserts in patients with DME. Patients were randomized in a 2:2:1 ratio
to the 0.2 µg per day FA implant, the 0.5 µg per day FA implant, or sham injection (saline).
The mean improvement in BCVA letter score between baseline and month 24 was 4.4 and 5.4
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in the low- and high-dose groups, respectively, compared with 1.7 in the sham group. Cataract
extraction was performed 74.9% of all phakic subjects at baseline in the low-dose insert group
and 84.5% in the high-dose insert group compared with 23.1% in the sham group.
Severely elevated intraocular pressure requiring glaucoma surgery occurred in 8.1% of
patients in the high dose group, 5.8% of patients in the low dose group, compared only 0.5%
in the sham treatment group [40].
This FA implant was approved in Europe (Austria, France, Germany, and Portugal) for the
treatment of DME unresponsive to all other therapies. However, it was recently denied
approval for this use by the US FDA, due to concerns centering on the high risk of severe
glaucoma.
7.2.1.3. Anti-vascular endothelial growth hormone compounds
Vascular Endothelial Growth Hormone (VEGF) is a subfamily of growth factors produced by
hypoxic cells that act as signal proteins to stimulate angiogenesis and vascular permeability.
One of the main drivers of diabetic eye disease is damage to retinal blood vessels leading to
tissue ischemia [41]. Hypoxic cells are then stimulated to release VEGF. Unsurprisingly,
elevated levels of VEGF have been demonstrated in the eyes of patients with diabetic retin‐
opathy [42,43]. Elevated VEGF stimulates both retinal vessel proliferation and increased
vascular permeability producing the macular edema seen in diabetic eye disease [44].
The injection of anti-VEGF agents to the vitreous is both effective and safe. Adverse ocular
effects with an incidence rate of less than 1% and include: cataract formation, retinal detach‐
ment, vitreous hemorrhage, and infection. Potential systemic adverse effects include: hyper‐
tension, stroke, and myocardial infarction but these are very uncommon [45]. Although there
is a theoretical risk for arterial thromboembolic events in patients receiving VEGF-inhibitors
by intravitreal injection, the observed incidence rate has been low in all studies and similar to
that seen in patients randomized to placebo [1,46].
Over the past 10 years, anti-VEGF agents have become the first line of therapy in treating DME.
There are three commercially available anti-VEGF agents: (i) Ranibizumab, (ii) Bevacizumab,
and (iii) Aflibercept.
Ranibizumab
Ranibizumab (Lucentis®; Genentech, South San Francisco, California) is a humanized
monoclonal antibody fragment directed at all isoforms of VEGF-A. Ranibizumab contains only
the Fab fragment of the parental anti-VEGF antibody with weight of 48 kDa. Several large
clinical trials have investigated the role of Ranibizumab in the treatment of diabetic macular
edema.
READ-2 [47] was a 6-month multicenter trial where patients were randomized in a 1:1:1
fashion to macular laser; monthly Ranibizumab; or a combination of laser and monthly
Ranibizumab. At 6 months, the combination therapy and Ranibizumab-only groups gained
3.80 and 7.2 letters at month 6, respectively, compared with no change in the laser only group.
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RESTORE [48] was a similar 12-month phase 3 clinical trial which compared Ranibizumab to
both laser alone and to laser combined with Ranibizumab. All patients receiving Ranibizumab
received three initial consecutive monthly injections followed by pro re nata (PRN, as needed)
injections as determined at the monthly examination. At month 12, both the Ranibizumab alone
and Ranibizumab with laser groups improved by 6 letters, while the laser alone group
remained nearly unchanged. Patients required a mean of seven Ranibizumab injections and
the change in vision was statistically significant.
As the data supporting Ranibizumab supplanting laser for primary treatment of center-
involving DME grew, many physicians were unsure of the continuing role of focal laser in
DME. To answer this among other questions, the DRCR.net [49,50] performed a randomized
trial which notably compared two methods of combining adjuvant laser with Ranibizumab
injections. In one arm of the study (prompt laser), focal laser was given to all the patients at
initiation and repeated every 4 months as needed. In the other arm (delayed laser), focal laser
could only be added if the edema persisted beyond 24 weeks of monthly Ranibizumab
treatment. After 3 years of follow-up, the average gain in the prompt laser group was 7 letters
compared with 10 letters in the delayed laser group. Based on these results, it is generally
accepted that treatment for center-involving DME should begin with an anti-VEGF agent.
Focal laser may be added only if the edema is persistent despite several consecutive anti-VEGF
injections. The FDA approved Ranibizumab for treatment of DME in 2012.
Bevacizumab
Bevacizumab (Avastin®; Genentech, South San Francisco, California) is a full-length recombi‐
nant humanized monoclonal immunoglobulin G1κ antibody weighing 149 kDa which
inactivates all VEGF isoforms. It was FDA-approved in 2004 as a treatment for colon cancer.
However, as emerging evidence pointed to VEGF as a central player in DME, ophthalmologists
began to use bevacizumab as an “off-label” treatment.
One of the criticisms of Bevacizumab use is that it has not been specifically formulated for
ocular use. Bevacizumab is sold in large vials intended for intravenous uses and compounding
pharmacies aliquot the medication into prefilled syringes for ocular use. Although there have
been case reports of contamination due to this extra step in the preparation process, the safety
of Bevacizumab for ocular use has been well established in trials for Age-related Macular
Degeneration with a side-effect profile similar to Ranibizumab [51].
Bevacizumab has yet to be approved by the FDA for use in DME. Despite this it is used in
many jurisdictions because of its efficacy and its significantly lower cost compared with
Ranibizumab. One study [52] estimated the cost of treating DME with Ranibizumab was 20-
fold higher than treating with Bevacizumab.
BOLT [53], a 2-year trial comparing bevacizumab monotherapy with focal laser, is the best
randomized trial supporting the use of Bevacizumab for center-involving DME. Eighty
patients with center-involved DME were randomized to receive either every 6-weekly
intravitreal bevacizumab injections (1.25 mg) or focal laser monotherapy.
At 2 years, there was a mean gain of 8.6 letters for Bevacizumab alone compared with a mean
loss of 0.5 letters in the laser group.
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Aflibercept
Aflibercept (EYLEA®-Regeneron Pharmaceuticals, Tarrytown, New York, NY, and Bayer
Healthcare Pharmaceuticals, Berlin, Germany) is a 115-kDa anti-VEGF agent. This protein was
developed by combining the extracellular binding domains of VEGF receptors1 and 2 to the
Fc segment of human immunoglobulin-G1.Similar to Ranibizumab and Bevacizumab,
Aflibercept binds to all isomers of the VEGF-A family.
The phase II DA VINCI [54] trial compared two doses of Aflibercept, 0.5 mg and 2.0 mg, to
laser treatment. The average improvement in visual acuity at 52 weeks was +11 letters for
monthly 0.5 mg, +13 letters for monthly 2.0 mg and −1 letters for laser alone.
A separate arm of this trial received 3 monthly 2 mg doses followed by a scheduled dose every
8 weeks. Patients in this arm received an average of 7.2 injections per year, as compared with
over 12 for monthly dosing. The average visual change was +10 letters. Ocular adverse events
were consistent with those seen in other trials with anti-VEGF drugs.
The recently completed phase III VIVID [55] and VISTA [56] trials were similarly designed.
Both supported the finding that a schedule of 5 monthly doses of Aflibercept followed by
regular bimonthly dosing was of similar efficacy to continuous monthly injections.
In 2014, FDA approved EYLEA for the treatment of diabetic macular edema. The recommend‐
ed dosage is 2 mg every 2 months, after five initial monthly injections.
Method of administration
The injection procedure should be carried out under aseptic conditions, which includes the
use of surgical hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid speculum
(or equivalent). Adequate anaesthesia and a broad-spectrum topical microbicide to disinfect
the periocular skin, eyelid and ocular surface should be administered prior to the injection, in
accordance with local practice.
The injection needle should be inserted 3.5-4.0 mm posterior to the limbus into the vitreous
cavity, avoiding the horizontal meridian and aiming toward the center of the globe. The
injection volume of 0.05 ml is then delivered.
The use of pre- or postinjection topical antibiotics is not recommended as they have not been
shown to alter the infection risk [57].
7.2.2. Nonproliferative diabetic retinopathy treatment
Visual acuity is not usually affected in nonproliferative diabetic retinopathy unless there is
damage to the macula in the form of macular edema or ischemia. Ocular treatment at this stage
is definitively indicated only if there is evidence of macular disease.
7.2.3. Proliferative diabetic retinopathy treatment
The goal of treatment in proliferative diabetic retinopathy (PDR) is to prevent complications
and lower the risk of severe vision loss. The mainstay of treatment for PDR is laser ablation of
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the peripheral retina where laser burns are placed over the entire retina, sparing the central
macula. This treatment is called panretinal photocoagulation (PRP). PRP promotes the
regression and arrest of progression of retinal neovascularizations by destroying ischemic
retinal tissue and reducing ischemia-driven VEGF production [1,10].
The Diabetic Retinopathy Study (DRS) [25,26] evaluated efficacy of PRP treatment in eyes
with advanced NPDR or PDR (DRS Group, 1981). The DRS study recommended prompt
treatment in eyes with high-risk PDR (defined in section 6.4.3), because these eyes had the
highest risk for severe visual loss. PRP treatment in these patients reduced the risk of severe
visual loss by 50% over 5 years.
The ETDRS study [24,58] found that PRP treatment in eyes with early PDR reduced the risk
of progression to high-risk PDR by 50%, and significantly reduced the risk of severe visual loss
[24]. Based on these results, PRP treatment should be considered in eyes with any stage PDR
especially if there is poor metabolic control, a noncompliant patient, or difficulty in maintain‐
ing close follow-up.
Figure 8. Panretinal photocoagulation: The retinal tissue surrounding the macular region has been ablated using Ar‐
gon laser. Circular grey-black scars demark areas previously treated with laser burns.
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Full PRP treatment as recommended by the DRS [25,26] and the ETDRS [24,58] includes as
many as 5000 laser burns. PRP can be painful and is often performed over several sessions.
After the initial treatment course, additional therapy can be applied if there is persistent
neovascularization. After treatment, proliferative retinal tissue may regress and contract
causing a vitreous hemorrhage or a traction retinal detachment from contracture of fibrovas‐
cular tissue. Side effects of PRP treatment also include decreased in night vision, decreased
color vision, and loss of peripheral vision [10].
When PDR presents with macular edema, PRP treatment may initially increase the amount of
edema [58]. In such case, it is recommended to treat the macular edema with an intravitreal
injection before initiating PRP [59,60].
7.2.3.1. Surgery in proliferative diabetic retinopathy
Vitrectomy surgery is most commonly performed in PDR for a dense vitreous hemorrhage
causing severe vision loss. If an eye which has not previously undergone PRP develops a
significant hemorrhage and vision loss, vitrectomy is recommended when the hemorrhage
persists beyond 1–3 months. Patients with vitreous hemorrhage that have preexisting complete
PRP may undergo a longer observation period as many patients will have a spontaneous
improvement beyond the initial 4 weeks [10,61]. Traction retinal detachment induced by the
contraction of neovascular tissue connecting the retinal surface to the vitreous is another
serious complication of PDR. If central vision is affected surgery is recommended. However,
traction detachments which do not involve the central macula can remain stable for years.
Surgery is indicated only when the traction retinal detachment involves or threatens the central
macula or if a retinal tear develops [10].
Common complications after vitrectomy include corneal epithelial defects, cataract formation,
elevated intraocular pressure, recurrent vitreous hemorrhage, iatrogenic retinal breaks, and
rhegmatogenous retinal detachment. The development of these complications can be mini‐
mized by meticulous surgical technique and cautious postoperative follow-up.
7.2.3.2. Role of anti-VEGF agents
Several studies have evaluated the efficacy of adjunctive intravitreal anti-VEGF injections in
patients with PDR [46]. Adding an anti-VEGF agent to eyes undergoing PRP reduces the risk
of a vitreous hemorrhage 12 months after PRP [62]. In eyes with PDR and a dense vitreous
hemorrhage, a Bevacizumab injection has been shown to aid significantly in clearing the
hemorrhage [63]. This allows PRP to be completed and may reduce the number of patients
ending up in surgery.
Bevacizumab has also been shown to enhance retinal surgery in patients with PDR. A single
Bevacizumab injection given 1 week before vitrectomy for vitreous hemorrhage, results in
decreased bleeding during surgery, decreased operating time, and less postoperative vitreous
hemorrhage as compared to vitrectomy [46,64]. As separate study found that a preoperative
Bevacizumab injection improved visual acuity 12 months postoperatively compared with
vitrectomy alone [62].




















Figure 9. Summary of the two main pathways by which diabetic retinopathy can reduce vision.
7.3. Special considerations
7.3.1. Diabetic retinopathy in pregnancy
In women with preexisting diabetes, pregnancy is considered an independent risk factor for
the development and progression of diabetic retinopathy [65]. Most of the progression of
diabetic retinopathy in pregnancy occurs by the end of the second trimester. Although
regression of retinopathy usually occurs postpartum, there is still an increased risk for
progression during the first year postpartum [65]. Risk factors for the development and
progression of diabetic retinopathy in pregnancy include longer duration of diabetes before
conception, rapid normalization of hemoglobin A1C at the beginning of pregnancy, poor
glycemic control during pregnancy, diabetic nephropathy, high blood pressure, and pree‐
clampsia [65,66].
Severity of diabetic retinopathy before or at beginning of pregnancy is also a strong predictor
of progression of retinopathy during and after pregnancy. The Diabetes in Early Pregnancy
Study [67] showed that 10.3% of women without diabetic retinopathy and 18.8% with mild
NPDR experienced retinopathy progression during pregnancy, and 6.3% of women with mild
NPDR progressed to PDR. In women with moderate NPDR, 54.8% suffered retinopathy
progression and 29% developed PDR. Overall, progression to sight-threatening diabetic
retinopathy, including macular edema and PDR, occurs in 6% of pregnant diabetic women [66].
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Progression of retinopathy during pregnancy is probably related to the hypervolemic and
hypercoagulable states in pregnancy, as well as elevated pro-inflammatory and angiogenic
factor levels. This results in capillary occlusion and leakage-aggravating diabetic retinopathy
mechanisms [65,68]. Ideally, good glycemic control and full treatment of preexisting diabetic
retinopathy complications should be attained before conception.
All diabetic women who plan pregnancy should be referred by their treating physician to an
ophthalmologist. The recommended follow-up of pregnant women with type 1 diabetes
includes an ophthalmologic exam at the beginning of pregnancy and during the first trimester.
Subsequent follow-up depends on the stage of diabetic retinopathy found on the initial
examinations. In women with no retinopathy or very mild NPDR, an ophthalmologic exam is
indicated when there are visual complaints. In moderate NPDR, an exam should be done at
least once during the second trimester and every 4–6 weeks during the third trimester. In severe
NPDR and PDR, close follow-up is needed, and an exam should be done every 4–6 weeks,
from the beginning of the second trimester.
Treatment of diabetic retinopathy during pregnancy includes maximal control of both glucose
levels and blood pressure [66]. Ocular therapy such as PRP should definitely be performed for
PDR and be strongly considered in cases of severe NPDR. Disease progression can be very fast
in pregnancy and waiting for PDR to clearly develop may result in severe complications that
necessitate invasive surgery. Ocular therapy for PDR and macular edema during pregnancy
can include PRP, focal laser, and intravitreal steroid injections. Although there are not much
data on the safety of intravitreal injections of anti-VEGF agents during pregnancy, the literature
includes some reports on the safe and effective use of Bevacizumab [69].
7.3.2. Cataract surgery in patients with diabetic retinopathy
Cataract development is major factor compromising vision in diabetic patients. Surgery often
results in significant vision improvements but these can be mitigated by the progression of
diabetic retinopathy and macular edema.
7.3.2.1. Macular edema progression following cataract extraction
Progression of macular edema following cataract extraction can limit the expected improve‐
ment in visual acuity from cataract surgery. The reported rates of macular edema following
cataract extraction varies from 4% to 70%, depending upon the method used to identify
macular edema (angiographic, biomicroscopic, OCT), the cataract extraction technique, and
underlying comorbidities [70,71].
The DRCR.net [72] conducted a multicenter, prospective, observational study including 293
participants with diabetic retinopathy but without significant macular edema requiring
treatment. The authors concluded that in eyes with diabetic retinopathy, the presence of
noncentral-involved macular edema immediately prior to cataract surgery, or a history of
macular edema treatment may increase the risk of developing central-involving macular
edema 16 weeks after cataract extraction.
Topical Nonsteroidal Anti-inflammatory Agents
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Controlling postsurgical inflammation is an important factor in preventing macular edema
development. Prostaglandin release considerably contributes to fluid leakage from perifoveal
capillaries into the extracellular space of the macular region. Multiple studies have reported
the benefits of using nonsteroidal anti-inflammatory eye drops pre- and postoperatively to
reduce the rate of edema progression [73,74].
Antivascular Endothelial Growth Factor Injections
Recent studies have shown a potential benefit using intravitreal anti-VEGF injections at the
end of cataract surgery especially in cases with poorly controlled or refractory macular edema
before surgery [46,75,76]. High-risk patients who received intravitreal Bevacizumab or
Ranibizumab benefit from better outcomes in terms of visual acuity, macular thickness, and
retinopathy progression.
7.3.2.2. Diabetic retinopathy progression following cataract extraction
Controversy exists in the ophthalmic community as to whether cataract surgery potentiates
diabetic retinopathy progression. Several studies have reported worsening of diabetic
retinopathy and macular edema after surgery [77-80]. Progression was seen during the first
year after surgery and was highest in the first 3 months postoperatively. A review of several
other studies, especially in the era of cataract surgery using the smaller incision phacoemul‐
sification technique, showed no significant progression of diabetic retinopathy and macular
edema after surgery [81,82]. Overall, it is likely that uncomplicated phacoemulsification does
not result in a substantially increased risk of the DR progression [83]. The observed rates of
progression after uncomplicated, small-incision surgery are similar to the natural course of
retinopathy progression over time. The vision improvement and the ability to better visualize
the retina to monitor retinopathy progression clearly outweigh the current risks of modern-
day cataract extraction and subsequent retinopathy progression over time [83], Overall,
diabetics with cataracts benefit from surgery, and improved visual acuity is reported in 92–
94% of patients [81]. The combined evidence suggests that in patients with low risk or absent
diabetic retinopathy, there is no increased risk of retinopathy progression. However, patients
with more advanced retinopathy have an increased risk for retinopathy progression and a
worse visual acuity outcome.
7.3.2.3. Summary
A thorough evaluation of patients with diabetes is warranted before cataract surgery. Patients
who have severe NPDR or PDR should be considered for PRP treatment prior to cataract
removal [84]. Patients with significant macular edema should undergo treatment with a steroid
or anti-VEGF agent preoperatively. Ideally, surgery should be delayed until stabilization of
retinopathy and macular edema is achieved. In refractory cases, adjunctive therapy with a
steroid of anti-VEGF agent at the end of cataract surgery should be considered. Close postop‐
erative follow-up with an ophthalmologist is highly recommended in all patients with
preexisting diabetic retinopathy.
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8. Schedule for ophthalmologic examinations
Regular ocular examination can detect early ocular disease such as cataracts and glaucoma as
well as retinopathy. Diabetic retinopathy in type 1 diabetes is rare during the first 5 years after
diagnosis, so the baseline ophthalmologic examination could be extended to 5 years after
diagnosis. In children with prepubertal diabetes, the baseline examination should be done at
puberty [13].
The timing and frequency of follow-up ocular examinations depends on individual patient’s
status. In high-risk patients with long-term diabetes and poor systemic risk factor control,
annual examinations should be performed even in the absence of retinopathy. In patients with
known retinopathy, the examination schedule is based on the degree of retinopathy, and on
the patient’s compliance and adherence to regular follow-up. In mild NPDR, an examination
should be performed every 9–12 months; in moderate NPDR, every 6 months; and in severe
NPDR, PDR and CSME follow-up should be even more frequent even in the absence of ongoing
treatment [10].
Severity ofRetinopathy Follow-up Schedule (Months)






Diabetic macular edema 1-3
NPDR = non-proliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy
Table 2. Diabetic retinopathy (follow-up recommendations)
9. Conclusion
Diabetes is the leading cause of vision loss in working-age patients, mainly due to diabetic
retinopathy. The mainstay in the prevention of disease progression remains optimizing
glycemic control and controlling other ancillary risk factors. Laser treatments which prevent
vision loss remain an important option for many patients with advanced diabetic retinopathy.
Recent advances in medical treatment over the past decade, especially intraocular injections
for macular edema, show great promise due to their ability to improve vision. Today, more
than ever before, patients with even advanced diabetic eye disease have a good chance of
maintaining functional vision for many years provided they undergo proper screening to
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diagnose complications as they arise. The cost of these new treatments is significant both in
financial terms and in terms of patient time investment, as frequent, often monthly, clinic visits
are often recommended to optimize results. Additional studies are still needed in order to
develop more effective and less costly treatments to further improve the visual prognosis for
diabetic patients.
Author details
Efraim Berco1,2, Daniel Rappoport1,2, Ayala Pollack1,2, Guy Kleinmann1,2 and
Yoel Greenwald1,2*
*Address all correspondence to: yoel.greenwald@gmail.com
1 Ophthalmology Department, Kaplan Medical Center, Rehovot, Israel
2 Hebrew University and Hadassah Medical School, Jerusalem, Israel
References
[1] Cheung N, Mitchell P,Wong TY. Diabetic Retinopathy. The Lancet 2010; 376: 124-36.
DOI: 10.1016/S0140-6736(09)62124-3.
[2] Fauci AS, Brownwald E, Kasper DL et al. (Eds.) McGraw-Hill Powers AC. Diabetes
Mellitus. Harrison’s Principles of Internal Medicine. Retrieved from: http://www.access‐
medicine.com
[3] Thomas D, Graham E. Ocular disorders associated with systemic disease. In: Rior‐
dan-Eva P & Whitcher JP (Eds.) Vaughan & Asbury’s General Ophthalmology, McGraw-
Hill,2008. Retrieved from: http://www.accessmedicine.com
[4] Kline LB, Tariq-Bhatti M, Chung SM et al. (Eds.) Section 5: Neuro-ophthalmology.
Basic and Clinical Science Course, -2011,American Academy of Ophthalmology. American
Academy of Ophthalmology.
[5] Leibowitz HM, Krueger DE, Dawber TR et al. The Framingham Eye Study mono‐
graph: An ophthalmological and epidemiological study of cataract, glaucoma, dia‐
betic retinopathy, macular degeneration, and visual acuity in a general population of
2631 adults, 1973-1975. Surv Ophthalmol 1980; 24:335-610
[6] Obrosova SS, Chung SS, Kador PF. Diabetic cataracts: mechanisms and management.
Diabetes/Metabol Res Rev 2010:26(3):172-180. DOI:10.1002/dmrr. 1075
Major Topics in Type 1 Diabetes54
[7] Bobrow JC, Blecher MH, Glasser D et al. (Eds.). Section 11: Lens and cataract. Basic
and Clinical Science Course, 2010-2011, American Academy of Ophthalmology. Americam
Academy of Ophthalmology.
[8] Purdy EP, Bolling JP, Di-Lorenzo AL et al. (Eds.) Endocrine disorders. In: Section 1:
Update on general medicine. Basic and Clinical Science Course 2010-2011, American
Academy of Ophthalmology. 2010; 189-205, American Academy of Ophthalmology.
[9] Reidy JJ, Bouchard CS, Florakis GJ et al. (Eds.) Metabolic disorders with corneal
changes. In: Section 8: External disease and cornea. Basic and Clinical Science Course
2010-2011, American Academy of Ophthalmology. 2010; 307-308. American Academy of
Ophthalmology.
[10] Regillo C, Holekamp N, Johnson MW et al. (Eds.) Retinal vascular disease: Diabetic
retinopathy. Section 12, Retina and vitreous. Basic and Clinical Science Course,
2010-2011, American Academy of Ophthalmology. 2010;109-132. American Academy of
Ophthalmology.
[11] Klein R, Knudtson MD, Lee KF et al. The Wisconsin Epidemiologic Study of Diabetic
Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with
type 1 diabetes. Ophthalmology 2008;115(11):1859-1868. doi: 10.1016/j.ophtha.
2008.08.023.
[12] Varma R. From a population to patients: The Wisconsin Epidemiologic Study of Dia‐
betic Retinopathy. Ophthalmology 2008; 115(11):1857-1858. DOI: 10.1016/j. ophtha.
2008.09.023.
[13] Raab EL, Aaby AA, Bloom JN et al. (Eds.) Vitreous and retinal diseases and disor‐
ders. In: Section 6: Pediatric ophthalmology and strabismus. Basic and Clinical Science
Course 2010-2011, American Academy of Ophthalmology. 2010; 296-297/ American Acad‐
emy of Ophthalmology.
[14] DCCT 1995: Progression of retinopathy with intensive versus conventional treatment
in the Diabetes Control and Complications Trial. Diabetes Control and Complica‐
tions Trial Research Group. Ophthalmology 1995;102(4): 647-661.
[15] Scanlon PH, Aldington SJ, Stratton IM. Epidemiological issues in diabetic retinop‐
athy. Middle East Afr J Ophthalmol 2014;20:293-300. DOI: 10.4103/0974-9233.120007
[16] Price SA, Gorelik A, Wentworth JM et al. Obesity is associated with retinopathy and
macrovascular disease in type 1 diabetes. Obes Res Clin Pract 2014;8:178-182. DOI:
10.1016/j.orcp.2013.03.007.
[17] Karamanos B, Porta M, Fuller JH et al. Different risk factors of microangionpathy in
patients with type 1 diabetes mellitus of short versus long duration. The EURODIAB
IDDM complications study. Diabetologia. 2000;43:348-355.
Management of Diabetic Retinopathy and Other Ocular Complications in Type 1 Diabetes
http://dx.doi.org/10.5772/61276
55
[18] DCCT 1997: Clustering of long term complications in families with diabetes in the
diabetes control and complications trial. The Diabetes Control and Complications
Trial Research Group. Diabetes 1997;46(11):1829-1839.
[19] Han L, Zhang L, Zhao J et al. The associations between VEGF gene polymorphisms
and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies. J
Diabetes Res 2014;2014 DOI:10.1155/2014/805801.
[20] Gallego PH, Craig ME, Donaghue KC et al. Role of blood pressure in development of
early retinopathy in adolescents with type 1 diabetes: Prospective cohort study. BMJ
2008;337: 918. DOI: 10.1136/bmj.a918.
[21] Harjutsalo V, Maric C, Groop PH, Finn Diane Study Group. Sex-related differences
in the long-term risk of microvascular complications by age at onset of type 1 diabe‐
tes. Diabetologia 2011;54:1992-1999. DOI: 10.1007/s00125-011-2144-2
[22] DCCT 2000: Effect of pregnancy on microvascular complications in the diabetes con‐
trol and complications trial. The Diabetes Control and Complications Trail Research
Group. Diabetes Care 2000; 23(8):1084-1091.
[23] Stirban A, Rosen P, Tschoepe D. Complications of type 1 diabetes: new molecular
findings. Mount Sinai J Med 2008; 75(4): 328-351. DOI: 10/1002/msj. 20057.
[24] ETDRS 1995: Focal photocoagulation treatment of diabetic macular edema: relation‐
ship of treatment effect to fluorescein angiographic and other retinal characteristics
at baseline. ETDRS Report 19. Early Treatment Diabetic Retinopathy Study Research
Group. Arch Ophthalmol 1995;113(9):1144-1155.
[25] DRS 1979: Four risk factors for severe visual loss in diabetic retinopathy. DRS Report
3. Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1979; 97(4): 654-655.
[26] DRS 1981: Photocoagulation treatment of proliferative diabetic retinopathy: clinical
application of Diabetic Retinopathy Study (DRS) findings. DRS Report 8. Diabetic
Retinopathy Study Research Group. Ophthalmology 1981;88(7):583-600.
[27] Chaturvedi N, Fuller JH, Aiello LP, EUCLID study Group. Circulating plasma vascu‐
lar endothelial growth factor and microvascular complications of type 1 diabetes
mellitus: the influence of ACE inhibition. Diabet Med. 2001;18:288-294.
[28] Venkatesh P, Ramanjulu R, Garg S et al. Subthreshold micropulse diode laser and
double frequency neodymium: YAG laser in treatment of diabetic macular edema: a
prospective, randomized study using multifocal electroretinography. Photomed Laser
Surg 2011;29:727-733. DOI: 10.1089/pho.2010.2830.
[29] Ingber DE, Madri JA, Folkman J. A possible mechanism for inhibition of angiogene‐
sis by angiostatic steroids: induction of capillary basement membrane dissolution.
Endocrinology1986;119(4):1768-1775.
Major Topics in Type 1 Diabetes56
[30] Stokes CL, Weisz PB, Williams SK et al. Inhibition of microvascular endothelial cell
migration by beta-cyclodextrin tetradecasulfate and hydrocortisone. Microvas Res
1990;40(2):279-284.
[31] Tokida Y, Aratani Y, Morita A et al. Production of two variant laminin forms by en‐
dothelial cells and shift of their relative levels by angiostatic steroids. J Biol Chem
1990;265(30):18123-9.
[32] Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C. Treatment of diabetic macular
edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide,
dexamethasone implant, and fluocinolone acetonide implant. Rev Expert Opin Phar‐
macother 2014;15:953-959. DOI: 10.1517/14656566.2014.896899
[33] Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treat‐
ment of diabetic macular edema. Am J Ophthalmol 2001;132:425-427.
[34] Martidis A, Duker JS, Baumal C et al. Intravitreal triamcinolone for refractory diabet‐
ic macular edema. Ophthalmology 2002;109:920-927.
[35] Sutter FK, Simpson JM, Gillies MC et al. Intravitreal triamcinolone for diabetic macu‐
lar edema that persists after laser treatment: three-month efficacy and safety results
of a prospective, randomized, double-masked, placebo-controlled clinical trial. Oph‐
thalmology 2004;111:2044-2049.
[36] DRCR network 2010a: The Diabetic Retinopathy Clinical Research Network.
Randomized trial evaluating Ranibizumab plus prompt or deferred laser or Triamci‐
nolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):
1067-1077. DOI: 10.1016/j.ophtha.2010.02.031.
[37] Callanan D, Gupta S, Boyer D et al. Dexamethasone intravitreal implant in combina‐
tion with laser photocoagulation for the treatment of diffuse diabetic macular edema.
Ophthalmology 2013;120;1843-1851. DOI: 10.1016/j.ophtha.2013.02.018
[38] Sadda S, Boyer D, He Yoon Y et al. Safety and efficacy of dexamethasone intravitreal
implant in patient with diabetic macular edema: phase III, 3 year, randomized, sham-
controlled study [MEAD]. 2014;10:1904-1914. DOI: 10.1016/j.ophtha.2014.04.024
[39] Campochiaro PA, Hafiz G, Shah SM et al. Famous Study Group. Sustained ocular de‐
livery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117(7):
1393-1399. DOI: 10.1016/j.ophtha.2009.11.024
[40] Campochiaro PA, Brown DM, Pearson A et al. Sustained delivery fluocinolone aceto‐
nide vitreous inserts provide benefit for at least 3 years in patients with diabetic mac‐
ular edema. Ophthalmology 2012;119(10):2125-2132. DOI: 10.1016/j.ophtha.2012.04.030
[41] Semenza GL. Vascular responses to hypoxia and ischemia. Arterioscler Thromb Vasc
Biol 2010; 30: 648-652. DOI: 10.1161/ATVBAHA.108.181644
Management of Diabetic Retinopathy and Other Ocular Complications in Type 1 Diabetes
http://dx.doi.org/10.5772/61276
57
[42] Funatsu H, Yamashita H, Hori S. et al. Angiotensin II and vascular endothelial
growth factor in the vitreous fluid of patients with diabetic macular edema and other
retinal disorders. Am J Ophthalmol 2002;133:537-543.
[43] Aiello LP, Avery RL, Park JE. et al. Vascular endothelial growth factor in ocular fluid
of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;
331:1480-1487.
[44] Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in
intraocular vascular disease. Ophthalmology 2013; 120: 106-114 DOI: 10.1016/j.ophtha.
2012.07.038
[45] Van der Reis MI, La Heij EC, Schouten JS et al. A systematic review of the adverse
events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011
Sep;31:1449-1469. DOI: 10.1097/IAE.0b013e3182278ab4.
[46] Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabet‐
ic retinopathy. Graefe’s Arch Clin Exper Ophthalmol 2010; 248(7): 915-930. DOI: 10.1007/
s00417-010-1315-z.
[47] Nguyen QD, Shah SM, Khwaja AA et al. Two-year outcomes of the ranibizumab for
edema of the macula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-2151.
DOI: 10.1016/j.ophtha.2010.08.016
[48] Schmidt Erfurth U, Lang GE, Holz FG et al. Three year outcomes of individualized
ranibizumab treatment in patients with diabetic macular edema. The RESTORE ex‐
tension study. Ahead of print. Ophthalmology 2014;121:1045-1053. DOI: 10.1016/
j.ophtha.2013.11.041
[49] Elman MJ, Aiello LP, Beck RW et al. Randomized trial evaluating ranibizumab plus
prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular
edema. Ophthalmology 2010;117:1064-1077.e35. DOI: 10.1016/j.ophtha.2014.08.047
[50] Elman MJ, Qin H, Aiello LP et al. Intravitreal ranibizumab for diabetic macular ede‐
ma with prompt versus deferred laser treatment: three-year randomized trial results.
Ophthalmology 2012; 119: 2312-2318. DOI: 10.1016/j.ophtha.2012.08.022
[51] Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Re‐
search Group, Martin DF,Ferris FL et al. Ranibizumab and bevacizumab for treat‐
ment of neovascular age-related macular degeneration: two-year results.
Ophthalmology 2012;119:1388-1398. DOI: 10.1016/j.ophtha.2012.03.053.
[52] Stefanini FR1, Arevalo JF, Maia M. Bevacizumab for the management of diabetic
macular edema. World J Diabetes 2013;4:19-26. DOI:10.4239/wjd.v4.i2.19.
[53] Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized control‐
led trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of
diabetic macular edema: 24-month data: Report 3. Arch Ophthalmol 2012;130(8):972–
979.
Major Topics in Type 1 Diabetes58
[54] DA VINCI Study Group. One-year outcomes of the DA VINCI study of VEGF trap-
eye in eyes with diabetic macular edema. Ophthalmology 2012;119(8):1658–1665. DOI:
10.1016/j.ophtha.2012.02.010
[55] Heier J. Intravitreal aflibercept for diabetic macular edema: 12 month efficacy and
safety results of phase 3, randomized, controlled VISTA-DME and VIVID-DME stud‐
ies. 2014.
[56] Diana D. Visual and anatomic outcomes from the VISTA-DME and VIVID-DME
studies of intravitreal aflibercept injection in diabetic macular edema patients with
and without prior treatment for DME. 2014.
[57] Storey P, Dollin M, Garg SJ et al. Post-Injection Endophthalmitis Study Team. The
role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal in‐
jection. Ophthalmology 2014 Jan;121:283-289. DOI: 10.1016/j.ophtha.2013.08.037.
[58] ETDRS 1991: Early photocoagulation for diabetic retinopathy. ETDRS Report 9. Early
Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5):
766-785.
[59] Silva PS, Sun JK, Aiello LP et al. Role of steroids in the management of diabetic mac‐
ular edema and proliferative diabetic retinopathy. Sem Ophthalmol 2009;24(2):93-99.
DOI: 10.1080/08820530902800355.
[60] Mirshahi A, Roohipoor R, Lashay A et al. Bevacizumab-augmented retinal laser pho‐
tocoagulation in proliferative diabetic retinopathy: a randomized double- masked
clinical trial. Eur J Ophthalmol 2008;18(2):263-269.
[61] El Annan J, Carvounis PE. Current management of vitreous hemorrhage due to pro‐
liferative diabetic retinopathy. Int Ophthalmol Clin 2014;54:141-153. DOI: 10.1097/IIO.
0000000000000027.
[62] Martinez-Zapata MJ, Marti-Crvajal AJ, Evans JR et al. Anti-vascular endothelial
growth factor for proliferative diabetic retinopathy. 2014;11. DOI:
10.1002/14651858.CD008721.pub2.
[63] Moradian S, Ahmadieh H, Malihi M. et al. Intravitreal Bevacizumab in active pro‐
gressive proliferative diabetic retinopathy. Graefe’s Arch Clin Exper Ophthalmol.
2008;246(12):1699-1705. DOI: 10.1007/s00417-008-0914-4.
[64] Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal Bevacizumab for
prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized
clinical trial. Ophthalmology 2010; 116:1943-1948. DOI: 10.1016/j.ophtha. 2009.07.001
[65] Shultz KL, Birnbaum AD, Goldsteir DA. Ocular disease in pregnancy. Curr Opin
Ophthalmol 2005;16(5):308-314.
Management of Diabetic Retinopathy and Other Ocular Complications in Type 1 Diabetes
http://dx.doi.org/10.5772/61276
59
[66] Vestgaard M, Ringholm L, Laugesen CS et al. Pregnancy-induced sight- threatening
diabetic retinopathy in women with type 1 diabetes. Diabet Med 2010; 27(4):431-435.
DOI: 10.1111/j.1464-5491.2010.02958.x.
[67] Chew EY, Mills JL, Metzger BE et al. Metabolic control and progression of retinop‐
athy. The Diabetic in Early Pregnancy Study. National Institute of Child Health and
Human Development. Diabetes in Early Pregnancy Study. Diabetes Care1995;18(5):
631-637.
[68] Kastelan S, Tomic M, Pavan J,Oreskovic S. Maternal immune system adaptation to
pregnancy – a potential influence on the course of diabetic retinopathy. Reproduct Biol
Endocrinol 2010;8:124-128. DOI: 10.1186/1477-7827-8-124.
[69] Tarantola RM, Folk JC, Culver Boldt H, Mahajan VB. Intravitreal Bevacizumab dur‐
ing pregnancy. Retina. 2010; 30(9): 1405-1411. DOI: 10.1097/IAE.0b013e3181f57d58.
[70] Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in pa‐
tients with diabetes using optical coherence tomography. Ophthalmology 2007 May;
114:881-889.
[71] Ostri C, Lund-Andersen H, La Cour M et al. Phacoemulsification cataract surgery in
a large cohort of diabetes patients: visual acuity outcomes and prognostic factors. J
Cataract Refract Surg 2011;37:2006-2011. DOI: 10.1016/j.jcrs.2011.05.030.
[72] Diabetic Retinopathy Clinical Research Network Authors/Writing Committee, Baker
CW, Almukhtar T, Stockdale C et al. Macular edema after cataract surgery in eyes
without preoperative central-involved diabetic macular edema. JAMA Ophthalmol
2013;131:870-879. DOI: 10.1001/jamaophthalmol.2013.2313.
[73] O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract sur‐
gery patient care. Curr Med Res Opin 2005 Jul;21:1131-1137.
[74] Singh R, Alpern L, Sager D et al. Evaluation of nepafenac in prevention of macular
edema followingcataract surgery in patients with diabetic retinopathy. Clin Ophthal‐
mol 2012;6:1259-1269. DOI: 10.2147/OPTH.S31902.
[75] Cheema RA, Al- Mubarak MM, Amin YM et al. Role of combined cataract surgery
and intravitreal Bevacizumab injection in preventing progression of diabetic retinop‐
athy; prospective randomized study. J Cataract Refract Surg 2009;35:18-25. DOI:
10.1016/j.jcrs.2008.09.019
[76] Chen CH, Liu YC, Wu PC. The combination of intravitreal Bevacizumab and phacoe‐
mulsification surgery in patients with cataract and coexisting diabetic macular ede‐
ma. J Ocular Pharmacol Therapeut 2009; 25,83-89. DOI: 10.1089/jop.2008.0068.
[77] Pollack A, Dotan S, Oliver M. Course of diabetic retinopathy following cataract sur‐
gery. Brit J Ophthalmol 1991;75(1):2-8.
Major Topics in Type 1 Diabetes60
[78] Hauser D, Katz H, Pokroy R. et al. Occurrence and progression of diabetic retinop‐
athy after phacoemulsification cataract surgery. J Cataract Refract Surg 2004; 30(2):
428-432.
[79] Jaffe GJ, Burton TC, Kuhn E. et al. Progression of nonproliferative diabetic retinop‐
athy and visual outcome after extracapsular cataract extraction and intraocular lens
implantation. Am J Ophthalmol 1992; 114(4):448-456.
[80] Hayashi K, Igrarashi C, Hirata A et al. Changes in diabetic macular edema after pha‐
coemulsification surgery. Eye (London). 2009; 23(2): 386-389.
[81] Rashid S, Young LH. Progression of diabetic retinopathy and maculopathy afterpha‐
coemulsification surgery. Int Ophthalmol Clin/ 2010; 50(1): 155-166. doi: 10.1097/IIO.
0b013e3181c555cf.
[82] Shah AS, Chen SH. Cataract surgery and diabetes. Curr Opin Ophthalmol. 2010:21(1):
4-9. doi: 10.1097/ICU.0b013e328333e9c1.
[83] Haddad NM, Sun JK, Silva PS et al. Cataract surgery and its complications in diabetic
patients. Rev Semin Ophthalmol 2014;29:329-337. DOI: 10.3109/08820538.2014.959197.
[84] Chew EY, Benson WE, Remaley NA et al. Results after lens extraction in patients
with diabetic retinopathy; early treatment diabetic retinopathy study report number
25. Arch Ophthalmol 1999:117(12):1600-1606.
Management of Diabetic Retinopathy and Other Ocular Complications in Type 1 Diabetes
http://dx.doi.org/10.5772/61276
61

